Chidamide with immunotherapy and anti-angiogenic drugs for advanced CRC
Part of Cancer clinical trials.
This study tests a combination of three drugs — Chidamide (a pill), an immunotherapy (PD-1/PD-L1 antibody), and anti-angiogenic agents (which block blood vessel growth to tumors) — for people with advanced colorectal cancer that has spread. The goal is to see how well they work together in real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your colorectal cancer has spread to other parts of the body (metastatic).
- You are able to be up and about at least half the day (ECOG 0–2).
- You have had at least one checkup to see how the cancer responded to past treatment.
- You are expected to live at least 3 more months.
- You have not already stopped the study drug 'Chidamide' after fewer than 2 treatment cycles.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study is looking at how well a combination of medications works for people with advanced colorectal cancer that is microsatellite stable (MSS). The medications include chidamide, a PD-(L)1 inhibitor (a type of immunotherapy), and anti-angiogenic therapy (a treatment that blocks blood vessel growth to tumors).
This trial tests a combination of four drugs (chidamide, a PD-1 inhibitor, bevacizumab, and XELOX chemotherapy) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
This trial tests a combination of two drugs (Adebrelimab and Chidamide) in people with advanced pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.